Compare · LTGO vs NVO

LTGO vs NVO

Side-by-side comparison of Latigo Biotherapeutics Inc. (LTGO) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both LTGO and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
  • NVO is the larger of the two at $180.22B, about 197.5x LTGO ($912.3M).
  • NVO has been more active in the news (9 items in the past 4 weeks vs 7 for LTGO).
  • NVO has more recent analyst coverage (25 ratings vs 0 for LTGO).
MetricLTGONVO
Company
Latigo Biotherapeutics Inc.
Novo Nordisk A/S
Price
-
-
Market cap
$912.3M
$180.22B
1M return
-
+5.96%
1Y return
-
-14.37%
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Exchange
NASDAQ
NYSE
IPO
2026
News (4w)
7
9
Recent ratings
0
25
LTGO

Latigo Biotherapeutics Inc.

Latigo Biotherapeutics is a private clinical-stage biopharmaceutical company committed to developing innovative non-opioid pain medicines designed to stop the transmission of pain without the risk of addiction, with the goal to provide effective, rapid-acting pain relief. Latigo is supported by leading investors, including Westlake Village BioPartners, Foresite Capital, 5AM Ventures, and Blue Owl Capital. Latigo's lead program is LTG-001, an oral, selective Nav1.8 inhibitor in development to treat acute pain.

NVO

Novo Nordisk A/S

Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.